SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) is a clinical-stage biopharmaceutical company developing cancer therapeutics for hematologic and solid tumor indications. Its two principal product candidates are galinpepimut-S (GPS), a peptide immunotherapy targeting the Wilms tumor 1 (WT1) antigen, and SLS009… From the company’s description.
In fiscal 2025, SELLAS Life Sciences Group, Inc. reported a net loss of $26.86M. Operations used $28.39M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What SELLAS Life Sciences Group, Inc. does
In the company’s own words
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) is a clinical-stage biopharmaceutical company developing cancer therapeutics for hematologic and solid tumor indications. Its two principal product candidates are galinpepimut-S (GPS), a peptide immunotherapy targeting the Wilms tumor 1 (WT1) antigen, and SLS009 (tambiciclib), a selective small-molecule CDK9 inhibitor. The company’s lead GPS program is a Phase 3 trial testing the therapy as maintenance treatment for acute myeloid leukemia (AML) patients in second remission. SLS009 is being studied for AML, including in an ongoing Phase 2 trial in newly diagnosed patients and a study in relapsed or refractory disease. SELLAS also holds worldwide rights to develop and commercialize SLS009 except in Greater China, and has licensed GPS rights in Greater China to 3D Medicines while retaining rights elsewhere. Its portfolio includes GPS+, a preclinical next-generation immunotherapy. SELLAS reported no product revenue and has no marketed products; its business centers on clinical development and relies on third parties for manufacturing and commercial capabilities.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1390478
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns SELLAS Life Sciences Group, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · SELLAS Life Sciences Group, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do SELLAS Life Sciences Group, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of SELLAS Life Sciences Group, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in SELLAS Life Sciences Group, Inc.'s last four quarterly filings that the numbers alone won't show?”